A Study to Assess the Safety and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
This 2 arm study will assess the safety and efficacy of tocilizumab monotherapy versus
methotrexate in patients with active rheumatoid arthritis (RA). Patients will be randomized
to receive tocilizumab 8mg/kg iv every 4 weeks plus placebo po weekly, or methotrexate
7.5-20mg po weekly plus placebo iv every 4 weeks. The anticipated time on study treatment is
3-12 months and the target sample size is 500+ individuals.